NovaTarg is approved for a $250,000 loan from the NC Biotech Center
NT1195 is selected as a drug candidate for the treatment of Type 2 Diabetes in patients with impaired renal function. IND-enabling studies begin.
NovaTarg has received $3.2 million in SBIR grant funding to further its discovery of tissue selective AMPK activators. NovaTarg plans to progress drug candidates for polycystic Kidney Disease and Type 2 Diabetes during this coming year.